纳米载药系统靶向肿瘤干细胞的研究进展

doi:10.11904/j.issn.1002-3070.2019.03.016

Abstract

Abstract: Cancer is one of the major diseases that seriously endanger human health.Recurrence and metastasis may still occur after traditional treatment.The basic reason is the presence of cancer stem cells(CSCs)in tumor tissues.CSCs have a high degree of proliferative ability,self-renewal,multi-directional differentiation,highly tumorigenicity and multi-drug resistance,which control the occurrence and development of tumors,chemotherapy tolerance,recurrence and metastasis.Therefore,clearing CSCs is one of effective ways to improve the curative rate of cancer.Nano-carriers have many advantages such as small size,large specific surface area,good biocompatibility and degradation in vivo.They are often used for targeted delivery and sustained release of drugs,which overcome the toxic side effects of traditional chemotherapeutic drugs,avoid surgical damage and kill CSCs.This paper will review the characteristics of CSCs and nano drug-loading systems as well as their research progress of nano drug-loading systems in CSCs in recent years.

Key words: Nano-drug delivery system, Cancer stem cell, Targeted therapy

CLC Number:

ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.

References

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
2 陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13.
3 Al-Hajj M,Wicha MS,Benito-Hernandezt A,et al.Prospective identification of tumorigenic breast cancer cells[J].P Natl Acad Sci USA,2003,100(7):3983-3988.
4 Cao S,Wang Z,Gao X,et al.FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC[J].J Exp Clin Cancer Res,2018,37(1):220.
5 Zhang Y,Zhang Q,Sun J,et al.The combination therapy of salinomycin and gefitinib using poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol)nanoparticles for targeting both lung cancer stem cells and cancer cells[J].Onco Targets Ther,2017,10:5653-5666.
6 Yang Y,Meng Q,Wang C,et al.MicroRNA 675 cooperates PKM2 to aggravate progression of human liver cancer stem cells induced from embryonic stem cells[J].J Mol Med,2018,96(10):1119-1130.
7 Aliebrahimi S,Kouhsari SM,Arab SS,et al.Phytochemicals,withaferin A and carnosol,overcome pancreatic cancer stem cells as c-Met inhibitors[J].Biomed Pharmacother,2018,106:1527-1536.
8 Kumar D,Gorain M,Kundu G,et al.Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma[J].Mol Cancer,2017,16(1):7.
9 李韶静,廖应芬,杜青.槲皮素纳米载药系统的研究与应用[J].中国中药杂志,2018,43(10):1978-1984.
10 Ajani JA,Song S,Hochster HS,et al.Cancer stem cells:The promise and the potential[J].Semin Oncol,2015,42:3-17.
11 崔畅畅,柯学,吕慧侠.肿瘤干细胞靶向治疗研究进展[J].药学进展,2016,40(1):20-29.
12 曹棉富,周代君,嘉桑摇,等.肿瘤干细胞的靶向治疗策略[J].医学研究生学报,2012,25(8):886-888.
13 何勤,刘亚圆.肿瘤靶向纳米载药系统的设计与构建[J].药学进展,2016,40(4):261-269.
14 訚亚涛,彭英.纳米载体在胶质瘤治疗中的研究进展[J].国际神经病学神经外科学杂志,2014,41(3):242-245.
15 杜锐凯,柳素玲.利用纳米技术靶向肿瘤干细胞的研究进展[J].科学通报,2015(35):3417-3423.
16 郭杏,冯雁,黄馨萍,等.代谢重编程及其与消化系统恶性肿瘤关系的研究进展[J].山东医药,2018,58(12):98-101.
17 Shen Y,Li W,Chen P,et al.Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol?-resistant ovarian cancer[J].Am J Transl Res,2015,7(5):841-855.
18 Liu Y,Mei L,Yu Q,et al.Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma[J].Acs Appl Mater Inter,2015,7(30):16792-16801.
19 Paula AD,Lopes C.Implications of different cancer stem cell phenotypes in breast cancer[J].Anticancer Res,2017,37(5):2173-2183.
20 Zhu Z,Hao X,Yan M,et al.Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma[J].Int J Cancer,2010,126(9):2067-2078.
21 Damelin M,Geles KG,Follettie MT,et al.Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells[J].Cancer Res,2011,71(12):4236-4246.
22 Leung EL,Fiscus RR,Tung JW,et al.Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties[J].PLoS One,2010,5(11):e14062.
23 Takaishi S,Okumura T,Tu S,et al.Identification of gastric cancer stem cells using the cell surface marker CD44[J].Stem Cells,2009,27(5):1006-1020.
24 Han N,Shin DH,Kim JS,et al.Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells[J].Int J Nanomed,2016,11:1413-1425.
25 Zhao P,Dong S,Bhattacharyya J,et al.iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors[J].Mol Pharmaceut,2014,11(8):2703-2712.
26 Wang X,Low XC,Hou W,et al.Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells[J].Acs Nano,2014,8(12):12151-12166.
27 Jang E,Kim E,Son H,et al.Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy[J].Biomaterials,2016,105:12-24.
28 王江峰,鲁莹,钟延强.聚氨基酯作为基因载体的研究进展[J].药学实践杂志,2011,29(3):165-168.
29 Lopez-Bertoni H,Kozielski KL,Rui Y,et al.Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival[J].Nano Lett,2018,18(7):4086-4094.
30 Cui F,Liu Q,Li R,et al.Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells[J].Int J Nanomed,2014,9:2345-2358.
31 Kim S,Rait A,Kim E,et al.A Nanoparticle Carrying the p53 gene targets tumors including cancer stem cells,sensitizes glioblastoma to chemotherapy and improves survival[J].Acs Nano,2014,8(6):5494-5514.
32 Islam F,Gopalan V,Wahab R,et al.Cancer stem cells in oesophageal squamous cell carcinoma:Identification,prognostic and treatment perspectives[J].Crit Rev Oncol Hemat,2015,96(1):9-19.
33 Roudi R,Korourian A,Shariftabrizi A,et al.Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes[J].Cancer Invest,2015,33(7):294-302.
34 Jing F,Kim HJ,Kim CH,et al.Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases[J].Int J Oncol,2015,46(4):1582-1588.
35 Wei X,He J,Wang J,et al.MPEG-CS/Bmi-1RNAi nanoparticles synthesis and its targeted inhibition effect on CD133+ laryngeal stem cells[J].J Nanosci Nanotechno,2018,18(3):1577-1584.
36 Sun R,Liu Y,Li S,et al.Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells[J].Biomaterials,2015,37:405-414.
37 Muntimadugu E,Kumar R,Saladi S,et al.CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel[J].Colloids and surfaces B:Biointerfaces,2016,143:532-546.

[1]	SUN Lichao,YANG Jing,SUN Lixin,ZHANG Yuan,YANG Zhihua,RAN Yuliang. Identification of monoclonal antibodies against hepatoma stem cells by screening for hepatoma spheroid cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 193-199.
[2]	HUANG Qianqian, MA Jianjia, WU Qiang, LIU Binbin, MU Xiaoqin, LIU Shulin. Research progress on tumor stem cells and tumor targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 533-537.
[3]	SUN Yuqi,CHEN Xiuwei. Research progress of CTGF/CCN2 in the development and targeted therapy of malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 363-366.
[4]	ZUO Zhichao, SU Danke, DENG Wenjuan, JIN Guanqiao. Recent advances of ELAM-1 in targeted cancer therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 444-447.
[5]	LV Fulian, GAO Xiang, JIN Aishun. Functional characteristic research progress of DCLK1 as a potential biomarker in cancer stem cells for gastrointestinal onalignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 458-461.
[6]	LIU Enrui,REN Huan,ZHAO Yu,SU Jun. Advanced research on characteristics of the classical subtype of human glioblastoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 136-139.
[7]	YAN Xiaofei,HAN Bo. The treatment and prospects of locally advanced nasopharyngeal carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 149-152.
[8]	LI Sen,LI Zhiguo,CHENG Long,XUE Yingwei. Progress of targeted therapy in Her-2 positive gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 188-192.
[9]	QIU Zidan,LI Jiancheng. Molecular targeted therapy for esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 57-60.
[10]	LUO Jianing,GE Xiaofeng. Drug treatment status and research progress on triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 89-92.
[11]	ZHANG Meng,ZHANG Jiewu,KONG Lingyu. The inhibition of skin tumor growth in Galectin-3-deficient mice [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 305-309.
[12]	MA RuiJin,YANG Yu. The research development of PI3K/AKT/mTOR signaling pathway in HER2 resistance for the treatment of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 360-363.
[13]	SONG chunyu,QU guofan. New progress in the study of gene- targeted threapy for osteosacoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 364-366.
[14]	REN Fenghai,XU Shidong. New development of PLK1 targeted therapy in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(5): 436-439.
[15]	WEI Tianli, QU Guofan. Recent progress on Wnt pathway and osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(4): 363-366.

Research progress of the nano drug-loading systems targeting tumor stem cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments